CA3024962C - Compose peptidique - Google Patents

Compose peptidique

Info

Publication number
CA3024962C
CA3024962C CA3024962A CA3024962A CA3024962C CA 3024962 C CA3024962 C CA 3024962C CA 3024962 A CA3024962 A CA 3024962A CA 3024962 A CA3024962 A CA 3024962A CA 3024962 C CA3024962 C CA 3024962C
Authority
CA
Canada
Prior art keywords
gly
arg
nmp
aib
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3024962A
Other languages
English (en)
Other versions
CA3024962A1 (fr
Inventor
Taiji Asami
Ayumu Niida
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Priority claimed from PCT/JP2017/019220 external-priority patent/WO2017204219A1/fr
Publication of CA3024962A1 publication Critical patent/CA3024962A1/fr
Application granted granted Critical
Publication of CA3024962C publication Critical patent/CA3024962C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

La présente invention concerne un composé peptidique utilisé pour le traitement ou la prévention de l’obésité, du diabète, entre autres. Plus particulièrement, la présente invention porte sur un composé peptidique de formule (I) : P1-Tyr-Aib-Glu-Gly-Thr-α-MePhe-Thr-Ser-Asp-Lys(-Gly-Gly-Gly-Gly-RA10) — A11-A12-Aib-Leu-A15-Lys-Gln-A18-Gln-Iva-Glu-Phe-Val-Arg-His-Leu-Leu-Asn-Lys-Aib-Thr-Arg-Gln-Arg-A35-NH2 (dans la formule, les symboles sont tels que définis dans la description), ainsi que sur le traitement ou la prévention de l’obésité, du diabète, etc. à l’aide du composé peptidique.
CA3024962A 2016-05-24 2017-05-23 Compose peptidique Active CA3024962C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2016-103011 2016-05-24
JP2016103011 2016-05-24
PCT/JP2017/019220 WO2017204219A1 (fr) 2016-05-24 2017-05-23 Composé peptidique

Publications (2)

Publication Number Publication Date
CA3024962A1 CA3024962A1 (fr) 2017-11-30
CA3024962C true CA3024962C (fr) 2025-08-12

Family

ID=

Similar Documents

Publication Publication Date Title
AU2014272500B2 (en) Peptide compound
US11174301B2 (en) Peptide compound
US10501516B2 (en) Peptide compound
WO2016084826A1 (fr) Composé peptidique
CA3024962C (fr) Compose peptidique
TWI770085B (zh) 胜肽化合物
HK40022800B (en) Gip receptor activating peptide
HK40022800A (en) Gip receptor activating peptide
EA044242B1 (ru) Пептидное соединение
BR112015027596B1 (pt) Peptídeo, sequência, medicamento, e, uso de um peptídeo